Saturday , November 27 2021

Highlights from the scientific sessions of the American Heart Association


This week, the gathering of news from the scientific sessions of the American Heart Association was the most talked about in cardiology. The scope of the meeting highlighted methods to improve CVD prevention, care about CVs and issues affecting patients and service providers. The meeting also presented new guidelines for cholesterol that highlighted new drugs and a more personal risk calculation.

The presentations contained several clinical trials. Findings from these studies have shown that icosapent ethyl reduces ischemic events in high-risk patients, dapagliflozin reduces hospitalization of cardiac insufficiency in patients with type 2 diabetes, and vitamin D and omega-3 do not manage to reduce major CV and cancer events.

Prevention is at the center of attention American Heart Association Scientific sessions

Scientific meetings of the American Heart Association, which will be held from 10 to 12 November in Chicago, will include the publication of two major guidelines focusing on cholesterol and physical activity, the presentation of an important science on CVD prevention, focusing on the use of technology to enhance care about CVs and a review of the high level of problems related to patients and service providers. Read more.

Cholesterol instructions are updated with newer drugs, personalized risk adjustments are adapted

CHICAGO – The New American Heart Association Cholesterol Guideline, the American College of Cardiology and 10 other societies recommend a step-by-step approach, including statin, ezetimibe and PCSK9 inhibitors in patients with previous CVD at a very high risk for the second event. Read more.

REDUCE-IT: Icosapent Ethyl reduces ischemic events in high-risk patients

CHICAGO – in patients with elevated triglycerides at high risk of CV in spite of statin therapy, icocapent ethyl was superior to placebo in order to reduce the risk for ischemic events, according to the results of the expected Reduce-IT trial. Read more.

DECLARE-TIMES 58: Daplagliflozin is decreasing heart failure hospitalization in type 2 diabetes

CHICAGO – The trial of dapagliflozine in DECLARE-TIMI 58 in patients with type 2 diabetes who have or who have been at high risk for atherosclerotic CVD adds an increasing amount of evidence that shows the beneficial effects of the SGLT2 inhibitor on CV risk. Read more.

VITAL: Vitamin D, omega-3 do not manage to reduce major CV events, cancer

CHICAGO – In a large-scale VITAL study, neither omega-3 or vitamin D supplements for primary prevention have reduced significant CV events or the development of invasive carcinoma compared with placebo over 5 years of follow-up. Read more.

Source link